505 related articles for article (PubMed ID: 25593335)
1. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
[TBL] [Abstract][Full Text] [Related]
2. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
[TBL] [Abstract][Full Text] [Related]
3. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
4. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
[TBL] [Abstract][Full Text] [Related]
6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.
Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn JY; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
Biol Blood Marrow Transplant; 2019 Feb; 25(2):270-278. PubMed ID: 30292009
[TBL] [Abstract][Full Text] [Related]
8. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.
Holtan SG; Zhang L; DeFor TE; Bejanyan N; Arora M; Rashidi A; Lazaryan A; Kotiso F; Blazar BR; Wagner JE; Brunstein CG; MacMillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1884-1889. PubMed ID: 31128328
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
11. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
12. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
Inagaki J; Fukano R; Noguchi M; Okamura J
Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066
[TBL] [Abstract][Full Text] [Related]
13. [Graft-versus-host disease-free, and relapse-free survival in Japanese patients with hematological malignancies].
Inamoto Y
Rinsho Ketsueki; 2018; 59(8):1101-1107. PubMed ID: 30185712
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
Tan J; Wang Y; Yu SJ; Ma YY; Lei HY; Liu QF
Leuk Res; 2017 Aug; 59():1-7. PubMed ID: 28527401
[TBL] [Abstract][Full Text] [Related]
17. Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG.
Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1868-1875. PubMed ID: 32640314
[TBL] [Abstract][Full Text] [Related]
18. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.
Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Ahmed I; Aljurf M; Askar M; Auletta JJ; Bhatt V; Bredeson C; Chhabra S; Gadalla S; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Inamoto Y; Kitko C; Khandelwal P; MacMillan ML; Majhail N; Marks DI; Mehta P; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Qayed M; Rangarajan H; Ringden O; Saad A; Savani BN; Seo S; Shah A; Shah N; Schultz KR; Solh M; Spitzer T; Szer J; Teshima T; Verdonck LF; Williams KM; Wirk B; Wagner J; Yared JA; Weisdorf DJ
Blood Adv; 2019 May; 3(9):1441-1449. PubMed ID: 31053571
[TBL] [Abstract][Full Text] [Related]
19. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
20. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Agrawal V; Ahmed I; Al-Homsi AS; Aljurf M; Antin JH; Askar M; Auletta JJ; Bhatt VR; Chee L; Chhabra S; Daly A; DeFilipp Z; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Hogan WJ; Inamoto Y; Martino R; Majhail NS; Marks DI; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Rangarajan HG; Ringden O; Saad A; Savani BN; Schoemans H; Seo S; Schultz KR; Solh M; Spitzer T; Storek J; Teshima T; Verdonck LF; Wirk B; Yared JA; Cahn JY; Weisdorf DJ
J Clin Oncol; 2020 Jun; 38(18):2062-2076. PubMed ID: 32364845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
